Codexis, Inc.: peers
Codexis, Inc. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Codexis, Inc.base CDXS · 🇺🇸 US Percentile in Healthcare Percentile in USA | Perspective Therapeutics, Inc. CATX · 🇺🇸 US Percentile in Healthcare Percentile in USA | Inovio Pharmaceuticals, Inc. INO · 🇺🇸 US Percentile in Healthcare Percentile in USA | Compass Therapeutics, Inc. CMPX · 🇺🇸 US Percentile in Healthcare Percentile in USA | TuHURA Biosciences, Inc. NV HURA · 🇺🇸 US Percentile in Healthcare Percentile in USA | Voyager Therapeutics, Inc. VYGR · 🇺🇸 US Percentile in Healthcare Percentile in USA | Armata Pharmaceuticals, Inc. ARMP · 🇺🇸 US Percentile in Healthcare Percentile in USA | Spruce Biosciences, Inc. SPRB · 🇺🇸 US Percentile in Healthcare Percentile in USA | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $140 MOct 26, 2026 · Market data3rd of 8 | $141 MOct 30, 2026 · Market data2nd of 8 | $144 MOct 30, 2026 · Market data1st of 8 | $137 MOct 29, 2026 · Market data4th of 8 | $135 MOct 30, 2026 · Market data5th of 8 | $134 MOct 14, 2026 · Market data6th of 8 | $130 MOct 28, 2026 · Market data7th of 8 | $130 MOct 26, 2026 · Market data8th of 8 | $136 M8 ranked |
| Revenue (Better neither way: ranked highest first) | $70 MFY2025 · SEC1st of 3 | —— | $0 MFY2025 · SEC3rd of 3 | —— | —— | $40 MFY2025 · SEC2nd of 3 | —— | —— | $40 M3 ranked |
| Net income (Higher is better) | $-44 MFY2025 · SEC3rd of 8 | $-103 MFY2025 · SEC6th of 8 | $-85 MFY2025 · SEC5th of 8 | $-66 MFY2025 · SEC4th of 8 | $-30 MFY2025 · SEC1st of 8 | $-120 MFY2025 · SEC7th of 8 | $-174 MFY2025 · SEC8th of 8 | $-39 MFY2025 · SEC2nd of 8 | $-76 M8 ranked |
| Employees (Better neither way: ranked highest first) | 261As on 2021 · Profile2nd of 6 | —— | 317As on 2021 · Profile1st of 6 | 39December 31, 2025 · Profile5th of 6 | 22December 31, 2025 · Profile6th of 6 | 141December 31, 2025 · Profile3rd of 6 | 61March 18, 2026 · Profile4th of 6 | —— | 1016 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | +18.6%FY2025 · SEC1st of 266th77th | ———— | ———— | ———— | ———— | -49.5%FY2025 · SEC2nd of 24th1st | ———— | ———— | -15.5%2 ranked |
| Revenue growth, 3 years a year (Higher is better) | -20.2%FY2025 · SEC2nd of 26th4th | ———— | ———— | ———— | ———— | -0.4%FY2025 · SEC1st of 226th31st | ———— | ———— | -10.3%2 ranked |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | 86.7%FY2025 · SEConly one with it88th95th | ———— | ———— | ———— | ———— | ———— | ———— | ———— | 86.7%— |
| Operating margin (Higher is better) | -59.3%FY2025 · SEC1st of 229th14th | ———— | ———— | ———— | ———— | -326.6%FY2025 · SEC2nd of 211th3rd | ———— | ———— | -192.9%2 ranked |
| Net margin (Higher is better) | -62.5%FY2025 · SEC1st of 228th13th | ———— | ———— | ———— | ———— | -296.6%FY2025 · SEC2nd of 211th4th | ———— | ———— | -179.5%2 ranked |
| Free cash flow margin (Higher is better) | -33.9%FY2025 · SEC1st of 231st14th | ———— | ———— | ———— | ———— | -334.6%FY2025 · SEC2nd of 211th3rd | ———— | ———— | -184.2%2 ranked |
| Return on equity (Higher is better) | -74.9%FY2025 · SEC4th of 732nd13th | -41.4%FY2025 · SEC2nd of 748th20th | -183.5%FY2025 · SEC7th of 712th5th | -41.3%FY2025 · SEC1st of 748th20th | -169.2%FY2025 · SEC6th of 713th6th | -48.3%FY2025 · SEC3rd of 744th19th | ———— | -109.3%FY2025 · SEC5th of 722nd10th | -74.9%7 ranked |
| Valuation | |||||||||
| Price to sales (Better neither way: ranked highest first) | 1.6×price Oct 26, 2026 · Market data2nd of 227th41st | ———— | ———— | ———— | ———— | 5.3×price Oct 14, 2026 · Market data1st of 258th79th | ———— | ———— | 3.5×2 ranked |
| Price to book (Better neither way: ranked highest first) | 2.8×price Oct 26, 2026 · Market data4th of 747th59th | 0.7×price Oct 30, 2026 · Market data6th of 712th11th | 6.0×price Oct 30, 2026 · Market data2nd of 772nd80th | 0.7×price Oct 29, 2026 · Market data5th of 712th12th | 6.5×price Oct 30, 2026 · Market data1st of 774th82nd | 0.7×price Oct 14, 2026 · Market data6th of 712th11th | ———— | 3.0×price Oct 26, 2026 · Market data3rd of 749th62nd | 2.8×7 ranked |
| Free cash flow yield (Higher is better) | -17.0%price Oct 26, 2026 · Market data1st of 835th16th | -67.4%price Oct 30, 2026 · Market data7th of 813th5th | -61.6%price Oct 30, 2026 · Market data6th of 815th6th | -35.9%price Oct 29, 2026 · Market data4th of 823rd10th | -20.5%price Oct 30, 2026 · Market data3rd of 832nd14th | -101.0%price Oct 14, 2026 · Market data8th of 87th3rd | -20.3%price Oct 28, 2026 · Market data2nd of 833rd15th | -43.1%price Oct 26, 2026 · Market data5th of 820th9th | -39.5%8 ranked |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | 0.8×FY2025 · SEC3rd of 369th60th | 0.0×FY2025 · SEC2nd of 310th7th | ———— | ———— | ———— | ———— | ———— | 0.0×FY2025 · SEC1st of 35th3rd | 0.0×3 ranked |
| Interest cover (Higher is better) | ———— | ———— | ———— | ———— | ———— | ———— | ———— | -405.7×FY2025 · SEConly one with it7th2nd | -405.7×— |
| Piotroski F-score (Higher is better) | 4 of 9FY2025 · SEConly one with it | —— | —— | —— | —— | —— | —— | —— | 4.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | 7 of 22FY2025 · Scorecard1st of 8 | 4 of 14FY2025 · Scorecard2nd of 8 | 2 of 13FY2025 · Scorecard7th of 8 | 2 of 10FY2025 · Scorecard3rd of 8 | 0 of 12FY2025 · Scorecard8th of 8 | 4 of 20FY2025 · Scorecard3rd of 8 | 2 of 11FY2025 · Scorecard6th of 8 | 3 of 15FY2025 · Scorecard3rd of 8 | 20% passed8 ranked |
| Valuation checks (Higher is better) | 2 of 5FY2025 · Scorecard1st of 8 | 1 of 4FY2025 · Scorecard3rd of 8 | 0 of 4FY2025 · Scorecard5th of 8 | 1 of 4FY2025 · Scorecard3rd of 8 | 0 of 4FY2025 · Scorecard5th of 8 | 2 of 5FY2025 · Scorecard1st of 8 | 0 of 4FY2025 · Scorecard5th of 8 | 0 of 4FY2025 · Scorecard5th of 8 | 13% passed8 ranked |
| Growth checks (Higher is better) | 1 of 6FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard3rd of 8 | 1 of 2FY2025 · Scorecard1st of 8 | 0 of 1FY2025 · Scorecard3rd of 8 | 0 of 2FY2025 · Scorecard3rd of 8 | 0 of 6FY2025 · Scorecard3rd of 8 | 0 of 2FY2025 · Scorecard3rd of 8 | 0 of 2FY2025 · Scorecard3rd of 8 | 0% passed8 ranked |
| Profitability checks (Higher is better) | 1 of 5FY2025 · Scorecard1st of 8 | 0 of 3FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard2nd of 8 | 0 of 5FY2025 · Scorecard2nd of 8 | 0 of 2FY2025 · Scorecard2nd of 8 | 0 of 3FY2025 · Scorecard2nd of 8 | 0% passed8 ranked |
| Financial health checks (Higher is better) | 3 of 5FY2025 · Scorecard2nd of 8 | 3 of 4FY2025 · Scorecard1st of 8 | 1 of 3FY2025 · Scorecard6th of 8 | 1 of 2FY2025 · Scorecard4th of 8 | 0 of 2FY2025 · Scorecard8th of 8 | 1 of 3FY2025 · Scorecard6th of 8 | 1 of 2FY2025 · Scorecard4th of 8 | 3 of 5FY2025 · Scorecard2nd of 8 | 50% passed8 ranked |
| Shareholder returns checks (Higher is better) | 0 of 1FY2025 · Scorecard3rd of 7 | 0 of 1FY2025 · Scorecard3rd of 7 | 0 of 1FY2025 · Scorecard3rd of 7 | —— | 0 of 1FY2025 · Scorecard3rd of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 1 of 1FY2025 · Scorecard1st of 7 | 0 of 1FY2025 · Scorecard3rd of 7 | 0% passed7 ranked |
| Ownership | |||||||||
| Held by institutions (Better neither way: ranked highest first) | 68.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 66.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 33.5%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 89.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 10.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 58.0%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 15.2%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 67.3%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 62.1%8 ranked |
| Institutions holding (Better neither way: ranked highest first) | 1302026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 8 | 1182026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 8 | 1112026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in5th of 8 | 1722026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 8 | 772026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in6th of 8 | 1212026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 8 | 642026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in8th of 8 | 702026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in7th of 8 | 1158 ranked |
| Institutional holding, change over the quarter (Better neither way: ranked highest first) | -8.3 pp2026-Q2 against 2026-Q1 · 13F7th of 8 | +4.0 pp2026-Q2 against 2026-Q1 · 13F2nd of 8 | -13.7 pp2026-Q2 against 2026-Q1 · 13F8th of 8 | -4.2 pp2026-Q2 against 2026-Q1 · 13F6th of 8 | -0.8 pp2026-Q2 against 2026-Q1 · 13F5th of 8 | +0.6 pp2026-Q2 against 2026-Q1 · 13F4th of 8 | +2.7 pp2026-Q2 against 2026-Q1 · 13F3rd of 8 | +15.3 pp2026-Q2 against 2026-Q1 · 13F1st of 8 | -0.1 pp8 ranked |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Codexis, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Perspective Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Inovio Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Compass Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; TuHURA Biosciences, Inc. NV: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Voyager Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Armata Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Spruce Biosciences, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Codexis, Inc. | -59.3%FY2025 | 29th percentile in Healthcaremedian -7.7%, 674 companies | 14th percentile in USAmedian 3.5%, 2,594 companies |
| Perspective Therapeutics, Inc. | — | — | — |
| Inovio Pharmaceuticals, Inc. | — | — | — |
| Compass Therapeutics, Inc. | — | — | — |
| TuHURA Biosciences, Inc. NV | — | — | — |
| Voyager Therapeutics, Inc. | -326.6%FY2025 | 11th percentile in Healthcaremedian -7.7%, 674 companies | 3rd percentile in USAmedian 3.5%, 2,594 companies |
| Armata Pharmaceuticals, Inc. | — | — | — |
| Spruce Biosciences, Inc. | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
| Fiscal year | Codexis, Inc. | Perspective Therapeutics, Inc. | Inovio Pharmaceuticals, Inc. | Compass Therapeutics, Inc. | TuHURA Biosciences, Inc. NV | Voyager Therapeutics, Inc. | Armata Pharmaceuticals, Inc. | Spruce Biosciences, Inc. |
|---|---|---|---|---|---|---|---|---|
| 2025 | $70 MSEC1st | — | $0 MSEC3rd | — | — | $40 MSEC2nd | — | — |
| 2024 | $59 MSEC2nd | — | $0 MSEC5th | $1 MSEC4th | — | $80 MSEC1st | — | $5 MSEC3rd |
| 2023 | $70 MSEC2nd | $1 MSEC4th | $1 MSEC5th | — | — | $250 MSEC1st | — | $10 MSEC3rd |
| 2022 | $139 MSEC1st | — | $10 MSEC3rd | — | — | $41 MSEC2nd | — | — |
| 2021 | $105 MSEC1st | $10 MSEC3rd | — | — | — | $37 MSEC2nd | — | — |
| 2020 | $69 MSEC2nd | $10 MSEC3rd | $7 MSEC4th | — | — | $171 MSEC1st | — | — |
| 2019 | $68 MSEC2nd | $7 MSEC3rd | $4 MSEC4th | — | — | $104 MSEC1st | — | — |
| 2018 | $61 MSEC1st | $6 MSEC4th | $30 MSEC2nd | — | — | $8 MSEC3rd | — | — |
| 2017 | $50 MSEC1st | $5 MSEC4th | $42 MSEC2nd | — | — | $10 MSEC3rd | — | — |
| 2016 | $49 MSEC1st | $5 MSEC4th | $35 MSEC2nd | — | — | $14 MSEC3rd | — | — |
| 2015 | $42 MSEC1st | $5 MSEC4th | $41 MSEC2nd | — | — | $17 MSEC3rd | — | — |
| 2014 | $35 MSEC1st | $4 MSEC3rd | $10 MSEC2nd | — | — | — | $0 MSEC4th | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Codexis, Inc.#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Perspective Therapeutics, Inc.CATX · 🇺🇸 USASame industry: Biotechnology · Similar size: $141 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $141 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Inovio Pharmaceuticals, Inc.INO · 🇺🇸 USASame industry: Biotechnology · Similar size: $144 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $144 M (Oct 30, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Compass Therapeutics, Inc.CMPX · 🇺🇸 USASame industry: Biotechnology · Similar size: $137 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $137 M (Oct 29, 2026) · revenue $0 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- TuHURA Biosciences, Inc. NVHURA · 🇺🇸 USASame industry: Biotechnology · Similar size: $135 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $135 M (Oct 30, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Voyager Therapeutics, Inc.VYGR · 🇺🇸 USASame industry: Biotechnology · Similar size: $134 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $134 M (Oct 14, 2026) · revenue $40 M (year to December 2025)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Armata Pharmaceuticals, Inc.ARMP · 🇺🇸 USASame industry: Biotechnology · Similar size: $130 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $130 M (Oct 28, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Spruce Biosciences, Inc.SPRB · 🇺🇸 USASame industry: Biotechnology · Similar size: $130 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $130 M (Oct 26, 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Sutro Biopharma, Inc.STRO · 🇺🇸 USASame industry: Biotechnology · Similar size: $155 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $155 M (Oct 26, 2026) · revenue $102 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Nkarta, Inc.NKTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $125 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $125 M (Oct 22, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Humacyte, Inc.HUMA · 🇺🇸 USASame industry: Biotechnology · Similar size: $125 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $125 M (Oct 28, 2026) · revenue $2 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Anavex Life Sciences Corp.AVXL · 🇺🇸 USASame industry: Biotechnology · Similar size: $123 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $123 M (Oct 26, 2026)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
- Foghorn Therapeutics Inc.FHTX · 🇺🇸 USASame industry: Biotechnology · Similar size: $123 M market cap against $140 M · Same country: USA · Ratios of the last two fiscal years on fileMarket cap $123 M (Oct 28, 2026) · revenue $31 M (year to December 2025)99 of 100 (industry or sector 50 + size 29 + country 15 + figures on file 5)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.